Nephro-Urology Monthly

Published by: Kowsar

A Systematic Review about an Advance in Cyclosporine Monitoring in Kidney Transplant Recipients

Behzad Einollahi 1 and Mojtaba Teimoori 2 , *
Authors Information
1 MD, Professor of Nephrology, Head of Nephrology and Urology Research Center, Baqiyatallah University of Medical Sciences, Tehran, IR Iran
2 MD, Urology Resident, Guilan University of Medical Sciences, Rasht, IR Iran
Article information
  • Nephro-Urology Monthly: July 2017, 9 (4); e24989
  • Published Online: March 11, 2017
  • Article Type: Review Article
  • Received: December 7, 2014
  • Revised: August 5, 2015
  • Accepted: February 25, 2017
  • DOI: 10.5812/numonthly.24989

To Cite: Einollahi B, Teimoori M. A Systematic Review about an Advance in Cyclosporine Monitoring in Kidney Transplant Recipients, Nephro-Urol Mon. 2017 ; 9(4):e24989. doi: 10.5812/numonthly.24989.

Copyright © 2017, Nephrology and Urology Research Center. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Context
2. Methods
3. Results
4. Discussion
  • 1. Wu AH. Creatine kinase isoforms in ischemic heart disease. Clin Chem. 1989; 35(1): 7-13[PubMed]
  • 2. Borel JF. History of the discovery of cyclosporin and of its early pharmacological development. Wien Klin Wochenschr. 2002; 114(12): 433-7[PubMed]
  • 3. Pritchard DI. Sourcing a chemical succession for cyclosporin from parasites and human pathogens. Drug Discov Today. 2005; 10(10): 688-91[DOI][PubMed]
  • 4. Starzl TE, Klintmalm GB, Porter KA, Iwatsuki S, Schroter GP. Liver transplantation with use of cyclosporin a and prednisone. N Engl J Med. 1981; 305(5): 266-9[DOI][PubMed]
  • 5. Ganong WF, Ganong W. Review of medical physiology. 1995;
  • 6. Mott JL, Zhang D, Freeman JC, Mikolajczak P, Chang SW, Zassenhaus HP. Cardiac disease due to random mitochondrial DNA mutations is prevented by cyclosporin A. Biochem Biophys Res Commun. 2004; 319(4): 1210-5[DOI][PubMed]
  • 7. Handschumacher RE, Harding MW, Rice J, Drugge RJ, Speicher DW. Cyclophilin: a specific cytosolic binding protein for cyclosporin A. Science. 1984; 226(4674): 544-7[PubMed]
  • 8. Youn TJ, Piao H, Kwon JS, Choi SY, Kim HS, Park DG, et al. Effects of the calcineurin dependent signaling pathway inhibition by cyclosporin A on early and late cardiac remodeling following myocardial infarction. Eur J Heart Fail. 2002; 4(6): 713-8[PubMed]
  • 9. Cheung A, Menkis AH. Cyclosporine heart transplantation. Transplant Proc. 1998; 30(5): 1881-4[PubMed]
  • 10. Nemati E, Einollahi B, Taheri S, Moghani-Lankarani M, Kalantar E, Simforoosh N, et al. Cyclosporine trough (C0) and 2-hour postdose (C2) levels: which one is a predictor of graft loss? Transplant Proc. 2007; 39(4): 1223-4[DOI][PubMed]
  • 11. Nankivell BJ, Hibbins M, Chapman JR. Diagnostic utility of whole blood cyclosporine measurements in renal transplantation using triple therapy. Transplantation. 1994; 58(9): 989-96[PubMed]
  • 12. Oellerich M, Armstrong VW, Schutz E, Shaw LM. Therapeutic drug monitoring of cyclosporine and tacrolimus. Update on Lake Louise Consensus Conference on cyclosporin and tacrolimus. Clin Biochem. 1998; 31(5): 309-16[PubMed]
  • 13. Cantarovich M, Barkun JS, Tchervenkov JI, Besner JG, Aspeslet L, Metrakos P. Comparison of neoral dose monitoring with cyclosporine through levels versus 2-hr postdose levels in stable liver transplant patients. Transplantation. 1998; 66(12): 1621-7[PubMed]
  • 14. Knoll G. Trends in kidney transplantation over the past decade. Drugs. 2008; 68 Suppl 1: 3-10[PubMed]
  • 15. Baczkowska T, Durlik M. Calcineurin inhibitor sparing immunosuppressive regimens in kidney allograft recipients. Pol Arch Med Wewn. 2009; 119(5): 318-25[PubMed]
  • 16. Mengel M, Chapman JR, Cosio FG, Cavaille-Coll MW, Haller H, Halloran PF, et al. Protocol biopsies in renal transplantation: insights into patient management and pathogenesis. Am J Transplant. 2007; 7(3): 512-7[DOI][PubMed]
  • 17. Levy G, Thervet E, Lake J, Uchida K, Consensus on Neoral CRITG. Patient management by Neoral C(2) monitoring: an international consensus statement. Transplantation. 2002; 73(9 Suppl)-8[PubMed]
  • 18. Press RR, Ploeger BA, den Hartigh J, van der Straaten T, van Pelt H, Danhof M, et al. Explaining variability in ciclosporin exposure in adult kidney transplant recipients. Eur J Clin Pharmacol. 2010; 66(6): 579-90[DOI][PubMed]
  • 19. Steimer W. Performance and specificity of monoclonal immunoassays for cyclosporine monitoring: how specific is specific? Clin Chem. 1999; 45(3): 371-81[PubMed]
  • 20. Schutz E, Svinarov D, Shipkova M, Niedmann PD, Armstrong VW, Wieland E, et al. Cyclosporin whole blood immunoassays (AxSYM, CEDIA, and Emit): a critical overview of performance characteristics and comparison with HPLC. Clin Chem. 1998; 44(10): 2158-64[PubMed]
  • 21. Holt DW, Jones K, Lee T, Stadler P, Johnston A. Quality assessment issues of new immunosuppressive drugs and experimental experience. Ther Drug Monit. 1996; 18(4): 362-7[PubMed]
  • 22. Holt DW, Johnston A, Kahan BD, Morris RG, Oellerich M, Shaw LM. New approaches to cyclosporine monitoring raise further concerns about analytical techniques. Clin Chem. 2000; 46(6 Pt 1): 872-4[PubMed]
  • 23. Batiuk TD, Pazderka F, Enns J, DeCastro L, Halloran PF. Cyclosporine inhibition of calcineurin activity in human leukocytes in vivo is rapidly reversible. J Clin Invest. 1995; 96(3): 1254-60[DOI][PubMed]
  • 24. von Ahsen N, Helmhold M, Schutz E, Eisenhauer T, Armstrong VW, Oellerich M. Cyclosporin A trough levels correlate with serum lipoproteins and apolipoproteins: implications for therapeutic drug monitoring of cyclosporin A. Ther Drug Monit. 1997; 19(2): 140-5[PubMed]
  • 25. Jorgensen KA, Koefoed-Nielsen PB, Karamperis N. Calcineurin phosphatase activity and immunosuppression. A review on the role of calcineurin phosphatase activity and the immunosuppressive effect of cyclosporin A and tacrolimus. Scand J Immunol. 2003; 57(2): 93-8[PubMed]
  • 26. Saas P, Tiberghien P. Dendritic cells: to where do they lead? Transplantation. 2002; 73(1 Suppl)-5[PubMed]
  • 27. Cattaneo D, Perico N, Remuzzi G. From pharmacokinetics to pharmacogenomics: a new approach to tailor immunosuppressive therapy. Am J Transplant. 2004; 4(3): 299-310[PubMed]
  • 28. Falck P, Asberg A, Guldseth H, Bremer S, Akhlaghi F, Reubsaet JL, et al. Declining intracellular T-lymphocyte concentration of cyclosporine a precedes acute rejection in kidney transplant recipients. Transplantation. 2008; 85(2): 179-84[DOI][PubMed]
  • 29. Caruso R, Perico N, Cattaneo D, Piccinini G, Bonazzola S, Remuzzi G, et al. Whole-blood calcineurin activity is not predicted by cyclosporine blood concentration in renal transplant recipients. Clin Chem. 2001; 47(9): 1679-87[PubMed]
  • 30. Vitko S, Tedesco H, Eris J, Pascual J, Whelchel J, Magee JC, et al. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant. 2004; 4(4): 626-35[DOI][PubMed]
  • 31. Keown PA. New concepts in cyclosporine monitoring. Curr Opin Nephrol Hypertens. 2002; 11(6): 619-26[DOI][PubMed]
  • 32. Citterio F, Scata MC, Romagnoli J, Nanni G, Castagneto M. Results of a three-year prospective study of C2 monitoring in long-term renal transplant recipients receiving cyclosporine microemulsion. Transplantation. 2005; 79(7): 802-6[PubMed]
  • 33. Perico N, Ruggenenti P, Gotti E, Gaspari F, Cattaneo D, Valente U, et al. In renal transplantation blood cyclosporine levels soon after surgery act as a major determinant of rejection: insights from the MY.S.S. trial. Kidney Int. 2004; 65(3): 1084-90[DOI][PubMed]
  • 34. Rodrigo E, Ruiz JC, Angeles de Cos M, Ruiz J, Gago M, Pinera C, et al. Correlation of C0 and C2 levels with cyclosporine side effects in kidney transplantation. Transplant Proc. 2009; 41(6): 2328-31[DOI][PubMed]
  • 35. Mendez A, Monforte V, Berastegui C, Lopez-Meseguer M, Bravo C, Pou L, et al. High intra-individual variability of cyclosporine pharmacokinetics in lung transplant recipients without cystic fibrosis. Clin Transplant. 2014; 28(6): 743-8[DOI][PubMed]
  • 36. Takasugi M, Takasugi JK, Barba L. Monitoring changes in cyclosporine dosage by trough level testing. Clin Transplant. 1995; 9(2): 98-105[PubMed]
  • 37. Hami M, Mojahedi MJ, Naghibi M, Shakeri MT, Sharifipour F. Cyclosporine trough levels and its side effects in kidney transplant recipients. Iran J Kidney Dis. 2010; 4(2): 153-7[PubMed]
  • 38. Matas AJ, Smith JM, Skeans MA, Thompson B, Gustafson SK, Schnitzler MA, et al. OPTN/SRTR 2012 Annual Data Report: kidney. Am J Transplant. 2014; 14 Suppl 1: 11-44[DOI][PubMed]
  • 39. Marin JG, Levine M, Ensom MH. Is C2 monitoring or another limited sampling strategy superior to C0 monitoring in improving clinical outcomes in adult liver transplant recipients? Ther Drug Monit. 2006; 28(5): 637-42[DOI][PubMed]
  • 40. Halloran PF, Helms LM, Kung L, Noujaim J. The temporal profile of calcineurin inhibition by cyclosporine in vivo. Transplantation. 1999; 68(9): 1356-61[PubMed]
  • 41. Stein CM, Murray JJ, Wood AJ. Inhibition of stimulated interleukin-2 production in whole blood: a practical measure of cyclosporine effect. Clin Chem. 1999; 45(9): 1477-84[PubMed]
  • 42. Hartel C, Fricke L, Schumacher N, Kirchner H, Muller-Steinhardt M. Delayed cytokine mRNA expression kinetics after T-lymphocyte costimulation: a quantitative measure of the efficacy of cyclosporin A-based immunosuppression. Clin Chem. 2002; 48(12): 2225-31[PubMed]
  • 43. Delgado DH, Rao V, Hamel J, Miriuka S, Cusimano RJ, Ross HJ. Monitoring of cyclosporine 2-hour post-dose levels in heart transplantation: improvement in clinical outcomes. J Heart Lung Transplant. 2005; 24(9): 1343-6[DOI][PubMed]
  • 44. Cantarovich M, Fitchett D, Latter DA. Cyclosporine trough levels, acute rejection, and renal dysfunction after heart transplantation. Transplantation. 1995; 59(3): 444-7[PubMed]
  • 45. Cole E, Maham N, Cardella C, Cattran D, Fenton S, Hamel J, et al. Clinical benefits of neoral C2 monitoring in the long-term management of renal transplant recipients. Transplantation. 2003; 75(12): 2086-90[DOI][PubMed]
  • 46. Di Paolo S, Teutonico A, Schena A, Infante B, Stallone G, Grandaliano G, et al. Conversion to C2 monitoring of cyclosporine A exposure in maintenance kidney transplant recipients: results at 3 years. Am J Kidney Dis. 2004; 44(5): 886-92[PubMed]
  • 47. Sitland TD, Kiberd B, Lawen J, Belitsky P. Conversion Of Long Term, Neoral Treated Kidney Transplant Recipients From C0 To C2 Monitoring. Am J Transplant Suppl. 2002; 2: 232
  • 48. Nashan B, Cole E, Levy G, Thervet E. Clinical validation studies of Neoral C(2) monitoring: a review. Transplantation. 2002; 73(9 Suppl)-11[PubMed]
  • 49. Cole E, Midtvedt K, Johnston A, Pattison J, O'Grady C. Recommendations for the implementation of Neoral C(2) monitoring in clinical practice. Transplantation. 2002; 73(9 Suppl)-22[PubMed]
  • 50. Oellerich M, Armstrong VW. Two-hour cyclosporine concentration determination: an appropriate tool to monitor neoral therapy? Ther Drug Monit. 2002; 24(1): 40-6[PubMed]
  • 51. Grant D, Kneteman N, Tchervenkov J, Roy A, Murphy G, Tan A, et al. Peak cyclosporine levels (Cmax) correlate with freedom from liver graft rejection: results of a prospective, randomized comparison of neoral and sandimmune for liver transplantation (NOF-8). Transplantation. 1999; 67(8): 1133-7[PubMed]
  • 52. Levy G, Burra P, Cavallari A, Duvoux C, Lake J, Mayer AD, et al. Improved clinical outcomes for liver transplant recipients using cyclosporine monitoring based on 2-hr post-dose levels (C2). Transplantation. 2002; 73(6): 953-9[PubMed]
  • 53. Cantarovich M, Besner JG, Barkun JS, Elstein E, Loertscher R. Two-hour cyclosporine level determination is the appropriate tool to monitor Neoral therapy. Clin Transplant. 1998; 12(3): 243-9[PubMed]
  • 54. Cantarovich M, Elstein E, de Varennes B, Barkun JS. Clinical benefit of neoral dose monitoring with cyclosporine 2-hr post-dose levels compared with trough levels in stable heart transplant patients. Transplantation. 1999; 68(12): 1839-42[PubMed]
  • 55. Kovarik JM, Kalbag J, Figueiredo J, Rouilly M, Frazier OL, Rordorf C. Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: a clinically relevant pharmacokinetic interaction. J Clin Pharmacol. 2002; 42(1): 95-9[PubMed]
  • 56. Filler G, Lepage N, Delisle B, Mai I. Effect of cyclosporine on mycophenolic acid area under the concentration-time curve in pediatric kidney transplant recipients. Ther Drug Monit. 2001; 23(5): 514-9[PubMed]
  • 57. Sindhi R, LaVia MF, Paulling E, McMichael J, Burckart G, Shaw S, et al. Stimulated response of peripheral lymphocytes may distinguish cyclosporine effect in renal transplant recipients receiving a cyclosporine+rapamycin regimen. Transplantation. 2000; 69(3): 432-6[PubMed]
  • 58. Levy GA. C2 monitoring strategy for optimising cyclosporin immunosuppression from the Neoral formulation. BioDrugs. 2001; 15(5): 279-90[PubMed]
  • 59. Einecke G, Mai I, Fritsche L, Slowinski T, Waiser J, Glander P, et al. Cyclosporin C2hour monitoring after renal transplantation. Int J Clin Pharmacol Ther. 2003; 41(10): 477-81[PubMed]
  • 60. Birsan T, Loinig C, Bodingbauer M, Wekerle T, Rockenschaub S, Berlakovich G, et al. Comparison between C0 and C2 monitoring in de novo renal transplant recipients: retrospective analysis of a single-center experience. Transplantation. 2004; 78(12): 1787-91[PubMed]
  • 61. Mahalati K, Belitsky P, Sketris I, West K, Panek R. Neoral monitoring by simplified sparse sampling area under the concentration-time curve: its relationship to acute rejection and cyclosporine nephrotoxicity early after kidney transplantation. Transplantation. 1999; 68(1): 55-62[PubMed]
  • 62. Banner NR, David OJ, Leaver N, Davis J, Breen J, Johnston A, et al. Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery. Transpl Int. 2002; 15(12): 649-54[DOI][PubMed]
  • 63. Ray E, Keogh AM, McLachlan AJ, Akhlaghi F. Cyclosporin C2 and C0 concentration monitoring in stable, long-term heart transplant recipients receiving metabolic inhibitors. J Heart Lung Transplant. 2003; 22(7): 715-22[DOI]
  • 64. Mahalati K, Lawen J, Kiberd B, Belitsky P. Is 3-hour cyclosporine blood level superior to trough level in early post-renal transplantation period? J Urol. 2000; 163(1): 37-41[PubMed]
  • 65. Kahan BD. Therapeutic drug monitoring of cyclosporine: 20 years of progress. 2004; 36
  • 66. Wong HS, Morad Z. Neoral (cyclosporine) C2 monitoring in renal transplant recipients: a single-center experience in Asia. Transplant Proc. 2003; 35(1): 230-1[PubMed]
  • 67. Dunn CJ, Wagstaff AJ, Perry CM, Plosker GL, Goa KL. Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation. Drugs. 2001; 61(13): 1957-2016[PubMed]
  • 68. Christiaans M, van Duijnhoven E, Beysens T, Undre N, Schafer A, van Hooff J. Effect of breakfast on the oral bioavailability of tacrolimus and changes in pharmacokinetics at different times posttransplant in renal transplant recipients. Transplant Proc. 1998; 30(4): 1271-3[PubMed]
  • 69. Morris RG, Russ GR, Cervelli MJ, Juneja R, McDonald SP, Mathew TH. Comparison of trough, 2-hour, and limited AUC blood sampling for monitoring cyclosporin (Neoral) at day 7 post-renal transplantation and incidence of rejection in the first month. Ther Drug Monit. 2002; 24(4): 479-86[PubMed]
  • 70. Keown P, Landsberg D, Halloran P, Shoker A, Rush D, Jeffery J, et al. A randomized, prospective multicenter pharmacoepidemiologic study of cyclosporine microemulsion in stable renal graft recipients. Report of the Canadian Neoral Renal Transplantation Study Group. Transplantation. 1996; 62(12): 1744-52[PubMed]
  • 71. Mahalati K, Belitsky P, West K, Kiberd B, Fraser A, Sketris I, et al. Approaching the therapeutic window for cyclosporine in kidney transplantation: a prospective study. J Am Soc Nephrol. 2001; 12(4): 828-33[PubMed]
  • 72. Lindholm A, Kahan BD. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clin Pharmacol Ther. 1993; 54(2): 205-18[PubMed]
  • 73. Senel MF, Van Buren CT, Welsh M, Kahan BD. Impact of early cyclosporin average blood concentration on early kidney transplant failure. Transpl Int. 1998; 11(1): 46-52[PubMed]
  • 74. Johnston A, Sketris I, Marsden JT, Galustian CG, Fashola T, Taube D, et al. A limited sampling strategy for the measurement of cyclosporine AUC. Transplant Proc. 1990; 22(3): 1345-6[PubMed]
  • 75. Grevel J, Kahan BD. Abbreviated kinetic profiles in area-under-the-curve monitoring of cyclosporine therapy. Clin Chem. 1991; 37(11): 1905-8[PubMed]
  • 76. Amante AJ, Kahan BD. Abbreviated area-under-the-curve strategy for monitoring cyclosporine microemulsion therapy in immediate posttransplant period. Clin Chem. 1996; 42(8 Pt 1): 1294-6[PubMed]
  • 77. Canadian Neoral Renal Transplantation Study G. Absorption profiling of cyclosporine microemulsion (neoral) during the first 2 weeks after renal transplantation. Transplantation. 2001; 72(6): 1024-32[PubMed]
  • 78. Woillard JB, Lebreton V, Neely M, Turlure P, Girault S, Debord J, et al. Pharmacokinetic tools for the dose adjustment of ciclosporin in haematopoietic stem cell transplant patients. Br J Clin Pharmacol. 2014; 78(4): 836-46[DOI][PubMed]
  • 79. Einecke G, Mai I, Fritsche L, Slowinski T, Waiser J, Neumayer HH, et al. The value of C2 monitoring in stable renal allograft recipients on maintenance immunosuppression. Nephrol Dial Transplant. 2004; 19(1): 215-22[PubMed]
  • 80. Lemahieu WP, Maes BD, Verbeke K, Vanrenterghem YF. Alterations of CYP3A4 and P-glycoprotein activity in vivo with time in renal graft recipients. Kidney Int. 2004; 66(1): 433-40[DOI][PubMed]
  • 81. Hebert MF. Contributions of hepatic and intestinal metabolism and P-glycoprotein to cyclosporine and tacrolimus oral drug delivery. Adv Drug Deliv Rev. 1997; 27(2-3): 201-14[PubMed]
  • 82. Lampen A, Christians U, Bader A, Hackbarth I, Sewing KF. Drug interactions and interindividual variability of ciclosporin metabolism in the small intestine. Pharmacology. 1996; 52(3): 159-68[PubMed]
  • 83. Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, et al. Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther. 1997; 62(3): 248-60[DOI][PubMed]
  • 84. Mueller EA, Kallay Z, Kovarik JM, Richard F, Wiesinger O, Schmidt K, et al. Bile-independent absorption of cyclosporine from a microemulsion formulation in liver transplant patients. Transplantation. 1995; 60(5): 515-7[PubMed]
  • 85. Xin HW, Liu HM, Li YQ, Huang H, Zhang L, Yu AR, et al. Association of CYP3A4*18B and CYP3A5*3 polymorphism with cyclosporine-related liver injury in Chinese renal transplant recipients. Int J Clin Pharmacol Ther. 2014; 52(6): 497-503[DOI][PubMed]
  • 86. Barnard JB, Thekkudan J, Richardson S, Bittar MN, Martyszczuck R, Hasan J, et al. Cyclosporine profiling with C2 and C0 monitoring improves outcomes after heart transplantation. J Heart Lung Transplant. 2006; 25(5): 564-8[DOI][PubMed]
  • 87. Thervet E, Pfeffer P, Scolari MP, Toselli L, Pallardo LM, Chadban S, et al. Clinical outcomes during the first three months posttransplant in renal allograft recipients managed by C2 monitoring of cyclosporine microemulsion. Transplantation. 2003; 76(6): 903-8[DOI][PubMed]
  • 88. Levy GA, Lake JR, Beauregard-Zollinger L, Prestele H. Improved Clinical Outcomes for Liver Transplant Recipients Using Cyclosporine Blood Level Monitoring Based on Two-Hour Post-Dose Levels. Transplantation. 2000; 69[DOI]
  • 89. Morton JM, Aboyoun CL, Malouf MA, Plit ML, Glanville AR. Enhanced clinical utility of de novo cyclosporine C2 monitoring after lung transplantation. J Heart Lung Transplant. 2004; 23(9): 1035-9[DOI][PubMed]
  • 90. Glanville AR, Hopkins PM, Aboyoun CL, Chhajed PN, Plit ML, Malouf MA. Clinical utility of cyclosporin C2 monitoring after lung transplantation (LTX). J Heart Lung Transplant. 2002; 21(1): 143[DOI]
  • 91. Villamil F, Pollard S. C2 monitoring of cyclosporine in de novo liver transplant recipients: the clinician's perspective. Liver Transpl. 2004; 10(5): 577-83[DOI][PubMed]
  • 92. Press RR, de Fijter JW, Guchelaar HJ. Individualizing calcineurin inhibitor therapy in renal transplantation--current limitations and perspectives. Curr Pharm Des. 2010; 16(2): 176-86[PubMed]
  • 93. Lindh JD, Andersson ML, Eliasson E, Bjorkhem-Bergman L. Seasonal variation in blood drug concentrations and a potential relationship to vitamin D. Drug Metab Dispos. 2011; 39(5): 933-7[DOI][PubMed]
  • 94. Ashavaid T, Raje H, Shalia K, Shah B. Effect of gene polymorphisms on the levels of calcineurin inhibitors in Indian renal transplant recipients. Indian J Nephrol. 2010; 20(3): 146-51[DOI][PubMed]
  • 95. Tang HL, Ma LL, Xie HG, Zhang T, Hu YF. Effects of the CYP3A5*3 variant on cyclosporine exposure and acute rejection rate in renal transplant patients: a meta-analysis. Pharmacogenet Genomics. 2010; 20(9): 525-31[DOI][PubMed]
  • 96. Zacher T, Thiele B, Wassmuth R, Albert FW. Cyclosporine A sensitivity in vitro and P-glycoprotein expression in patients on dialysis and after kidney transplantation. Transpl Immunol. 2000; 8(2): 147-50[PubMed]
  • 97. Zhang Y, Li JL, Fu Q, Wang XD, Liu LS, Wang CX, et al. Associations of ABCB1, NFKB1, CYP3A, and NR1I2 polymorphisms with cyclosporine trough concentrations in Chinese renal transplant recipients. Acta Pharmacol Sin. 2013; 34(4): 555-60[DOI][PubMed]
  • 98. Einollahi B, Rostami Z, Teimoori M. Human leukocyte antigen variation among Iranian renal transplant recipients. J Nephropathol. 2012; 1(3): 164-9[DOI][PubMed]
  • 99. Nemati E, Taheri S, Pourfarziani V, Einollahi B. Human leukocyte antigen (HLA) B-27 and older age are associated with augmented cyclosporine blood bioavailability in renal allograft recipients: an attempt toward individualization of immunosuppression. Ann Transplant. 2008; 13(2): 32-6[PubMed]
  • 100. Elens L, Hesselink DA, Bouamar R, Budde K, de Fijter JW, De Meyer M, et al. Impact of POR*28 on the pharmacokinetics of tacrolimus and cyclosporine A in renal transplant patients. Ther Drug Monit. 2014; 36(1): 71-9[DOI][PubMed]
  • 101. Einollahi B, Teimoori M, Rostami Z. Change of Cyclosporine Absorption over the Time after Kidney Transplantation. Nephrourol Mon. 2012; 4(2): 470-4[DOI][PubMed]
  • 102. Sanchez R, Picard N, Mouly-Bandini A, Chalvignac V, Lacarelle B, Sampol-Manos E. Severe decrease of cyclosporine levels in a heart transplant recipient receiving the direct thrombin inhibitor argatroban. Ther Drug Monit. 2014; 36(3): 273-7[DOI][PubMed]
  • 103. Tornatore KM, Brazeau D, Dole K, Danison R, Wilding G, Leca N, et al. Sex differences in cyclosporine pharmacokinetics and ABCB1 gene expression in mononuclear blood cells in African American and Caucasian renal transplant recipients. J Clin Pharmacol. 2013; 53(10): 1039-47[DOI][PubMed]
  • 104. Roos K, Gotthardt D, Giese T, Schnitzler P, Stremmel W, Czock D, et al. Pharmacodynamic monitoring of immunosuppressive effects indicates reduced cyclosporine activity during telaprevir therapy. Liver Transpl. 2014; 20(9): 1106-17[DOI][PubMed]
  • 105. Carrier M, White M, Pellerin M, Pelletier GB, Pelletier LC. Comparison of Neoral and Sandimmune cyclosporine for induction of immunosuppression after heart transplantation. Can J Cardiol. 1997; 13(5): 469-73[PubMed]
  • 106. Moes DJ, Swen JJ, den Hartigh J, van der Straaten T, van der Heide JJ, Sanders JS, et al. Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation. CPT Pharmacometrics Syst Pharmacol. 2014; 3[DOI][PubMed]
  • 107. Zhou H, Gao Y, Cheng XL, Li ZD. Population pharmacokinetics of cyclosporine A based on NONMEM in Chinese allogeneic hematopoietic stem cell transplantation recipients. Eur J Drug Metab Pharmacokinet. 2012; 37(4): 271-8[DOI][PubMed]
  • 108. Cooney GF, Jeevanandam V, Choudhury S, Feutren G, Mueller EA, Eisen HJ. Comparative bioavailability of Neoral and Sandimmune in cardiac transplant recipients over 1 year. 1998; 30
  • 109. Tan KK, Trull AK, Hue KL, Best NG, Wallwork J, Higenbottam TW. Pharmacokinetics of cyclosporine in heart and lung transplant candidates and recipients with cystic fibrosis and Eisenmenger's syndrome. Clin Pharmacol Ther. 1993; 53(5): 544-54[PubMed]
  • 110. Kalyoncu M, Topaloglu R, Bayrakci U, Bakkaloglu A, Besbas N, Ozaltin F, et al. Cyclosporine drug monitoring with C0 and C2 concentrations in children with stable renal allograft function. Pediatr Transplant. 2006; 10(2): 168-71[DOI][PubMed]
  • 111. Sommerer C, Giese T, Meuer S, Zeier M. Pharmacodynamic monitoring of calcineurin inhibitor therapy: is there a clinical benefit? Nephrol Dial Transplant. 2009; 24(1): 21-7[DOI][PubMed]
  • 112. Einollahi B, Teimoori M. Cyclosporine trough level monitoring. Iran J Kidney Dis. 2011; 5(3): 211-2[PubMed]
  • 113. Marquet P. Pretransplantation calcineurin activity: towards individualized therapy? Liver Int. 2009; 29(10): 1454-6[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments